

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/bjbas



Synthesis and antimicrobial evaluation of certain purine, benzothiazole and thiazole systems substituted with dialkylaminoalkyl-o-cresols



Khaled R.A. Abdellatif^{*a*,*}, Ghada A. Abd El Wareth^{*a*}, Ossama M. El-Badry^{*b*}, Hamdy M. Ragab^{*b*}, Mervat M. El-Enany^{*b*}

^a Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, 62514, Beni-Suef, Egypt

^b Department of Organic Chemistry, Faculty of Pharmacy, Cairo University, ElKasr Eleini Street, 11562, Cairo, Egypt

ARTICLE INFO

Article history: Received 22 November 2014 Accepted 16 January 2015 Available online 28 February 2015

Keywords: Purine Benzothiazole Thiazole o-cresols Antimicrobial activity

A B S T R A C T

Novel series of dialkylaminoalkyl-o-cresols incorporated with purine nucleus 2a-b, benzothiazole nucleus 5a-b, 8a-b and thiazole nucleus 11a-d, 13a-d were synthesized through Mannich reaction. Structures of the newly synthesized compounds have been deduced on the basis of elemental analysis and spectral data. Antimicrobial activity evaluation was carried out for all synthesized compounds; most of them exerted comparable activity to ciprofloxacin and flucanazole. The thiazole derivatives 11a, 13c, 13d are the most potent compounds.

Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

1. Introduction

The resistance to antimicrobial drugs is widespread; there is an increasing need for identification of novel structure leads that may be of use in designing new, potent and less toxic antimicrobial agents. The previous literature survey revealed that certain phenolic Mannich bases (Magarian and Sorenson, 1976; Pernak et al., 1999), purine (Bakkestuen et al., 2000; Gundersen et al., 2002), benzothiazole (Abdel-Rahman and Morsy, 2007; Hilal et al., 2006; Vicini et al., 2008; Yamazaki et al., 2005) and thiazole (Bozdag-Dundar et al., 2007;

http://dx.doi.org/10.1016/j.bjbas.2015.02.008

Karegoudar et al., 2008; Ozdemir et al., 2007; Vicini et al., 2006) derivatives exhibited significant antibacterial and antifungal activities. At the same time, presence of azo group (Bondock et al., 2007) or azomethine group (Chohan et al., 2003) enhances the antimicrobial activity of the above mentioned nuclei. Also, the introduction of an amidic linkage into the heteroaromatic ring systems increases its biological activity by increasing the lipophilicity of these compounds which facilitates their penetration into the bacterial and fungal cells (Turan-Zitouni et al., 2004, 2005; Zimenkovskii et al., 2006). In view of the aforementioned findings, it was

^{*} Corresponding author. Tel.: +20 100 2535444; fax: +20 082 2317958.

E-mail address: khaled.ahmed@pharm.bsu.edu.eg (K.R.A. Abdellatif). Peer review under the responsibility of Beni-Suef University.

^{2314-8535/}Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

interesting to make a link between phenolic Mannich bases and some heteroaromatic ring systems *via* one of the above pharmacophoric groups. Accordingly and in continuation of our previous work (Abdellatif et al., 2014), we now report combination between purine nucleus with dialkylamino-ocresol moieties *via* an amidic linkage (2a–b), or an incorporation of a benzothiazole ring system with phenolic Mannich bases through the pharmacophoric azomethine group (5a–b) or *via* an amidic linkage (8a–b). Moreover, a number of substituted thiazoles incorporated with dialkylamino-o-cresol moieties *via* azo group (11a–d, 13a–d) with the aim that the target compounds may show good antimicrobial activity.

2. Experimental

2.1. Chemistry

2.1.1. General

Melting points were determined on a Griffin apparatus and are uncorrected. Infrared (IR) spectra were recorded on a Shimadzu 435 Spectrometer, using KBr discs and values were represented in cm-1. ¹H NMR spectra were measured on a Varian Gemini 300 MHz spectrometer in CDCl₃ or DMSO-d₆ with TMS as the internal standard. Mass spectra were run on Hewlett Packard 5988 spectrometer. Microanalyses were performed for C, H, N (Micro Analytical Centre, Cairo University, Egypt) and were within ± 0.4% of theoretical values. Progress of the reactions was monitored by TLC using TLC sheets precoated with UV fluorescent silica gel MERCK 60 F 254 that was visualized by UV lamp. 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6tetrahydropurin-7-yl)-N-(4-hydroxyphenyl)acetamide (1), 4benzothiazol-2-yl-phenylamine (3) (Shi et al., 1996), 4-[(4benzothiazol-2-yl-phenylimino)-methyl]-phenol (4)(Nagarajan et al., 2010), N-(4-benzothiazol-2-yl-phenyl)-2chloroacetamide (6) (Chua et al., 1999; Pan et al., 2013), 4phenylthiazol-2-ylamine (9a) (Dodson and King, 1945), 4-(4methylphenyl)thiazol-2-ylamine (9b) (King and Hlavacek, 1950), 2-amino-4-methylthiazole-5-carboxylic acid ethyl ester (9c) (Dodson and King, 1945), 4-(4-phenylthiazol-2-ylazo) phenol (10a), and 2-(4-hydroxy-phenylazo)-4-methylthiazole-5-carboxylic acid ethyl ester (10b) were prepared according to reported procedures.

2.1.1.1. N-(3-Diethylaminomethyl-4-hydroxyphenyl)-2-(1,3-

dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)acetamide (2a). To a solution of the purine derivative 1 (1.64 gm, 5 mmol) in dimethylformamide (15 mL), a mixture of diethylamine (6 mmol) and formaldehyde solution (37–40%) (0.62 mL, 7.5 mmol) in glacial acetic acid (5 mL) was added drop wise. After complete addition, the reaction mixture was stirred at room temperature for 12 h then poured onto ice-cooled water. The formed precipitate was filtered, dried and crystallized from dimethylformamide/water to afford 1.39 g of **2a** (67% yield); mp 249–250°; IR (cm⁻¹) 3306, 3257 (OH & NH), 3162, 3086 (CH aromatic), 2984, 2878 (CH aliphatic), 1703, 1651 (amidic C= O), 1555 (C=N), 1518 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 0.95 (t, *J* = 7.5 Hz, 6H, <u>H</u>₃C-H₂C-N-CH₂-C<u>H</u>₃), 2.74 (q, *J* = 7.5 Hz, 4H, H₃C-<u>H</u>₂C-N-C<u>H</u>₂-CH₃), 3.17 (s, 3H, purinyl N3-C<u>H</u>₃), 3.42 (s, 3H, purinyl N1-CH₃), 3.55 (s, 2H, CH₂N); 5.13 (s, 2H, CH₂CO), 6.68–6.72 (m, 2H, phenyl H-2, H-6), 7.35 (d, J = 8.1 Hz, 1H, phenyl H-5), 8.04 (s, 1H, purinyl H-8), 9.33 (s, 1H, N<u>H</u>, D₂O exchangeable), 10.17 (s, 1H, O<u>H</u>, D₂O exchangeable); EIMS 414 (M⁺). Anal. Calcd for C₂₀H₂₆N₆O₄: C, 57.96; H, 6.32; N, 20.28. Found: C, 58.22; H, 6.29; N, 20.40.

2.1.1.2. 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-

yl)-N-[4-hydroxy-3-(4-methylpiperidin-1-ylmethyl)-phenyl]acetamide (2b). The title compound 2b was synthesized, using a similar procedure to that described for the preparation of 2a, by using 4-methylpiperidine in place of diethylamine, in 80% yield as a pale brown powder; mp 188–190 $^{\circ}$ C; IR (cm⁻¹) 3300, 3200 (OH & NH), 3160, 3058 (CH aromatic), 2948, 2809 (CH aliphatic), 1705, 1659 (amidic C=O), 1548 (C=N), 1495 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 0.92 (d, J = 7.2 Hz, 3H, piperidine CH₃), 1.27–1.43 (m, 5H, piperidinyl H-3, H-4, H-5), 2.13 (t, J = 5.4 Hz, 4H, piperidinyl H-2, H-6), 3.41 (s, 3H, purinyl N3-CH₃), 3.58 (s, 3H, purinyl N1-CH₃), 3.66 (s, 2H, CH₂N), 4.99 (s, 2H, CH₂CO), 6.70-6.73 (m, 2H, phenyl H-2, H-6), 7.33 (d, *J* = 8.1 Hz, 1H, phenyl H-5), 7.77 (s, 1H, purinyl H-8), 9.31 (s, 1H, NH, D₂O exchangeable), 10.41 (s, 1H, OH, D₂O exchangeable); EIMS 441 (M + 1). Anal. Calcd for C₂₂H₂₈N₆O₄: C, 59.99; H, 6.41; N, 19.08. Found: C, 60.14; H, 6.19; N, 18.84.

2.1.1.3. 4-[(4-benzothiazol-2-yl-phenylimino)methyl]-2-

dimethylaminomethylphenol (5a). A mixture of dimethylamine (0.005 mol) and formaldehyde solution (37-40%) (0.4 mL, 0.005 mol) in absolute ethanol (5 mL) was added to a solution of 4-[(4-benzothiazol-2-yl-phenylimino)-methyl]-phenol (4) (1.65 gm, 0.005 mol) in absolute ethanol (10 mL). The reaction mixture was heated under reflux for 5 h, allowed to cool to room temperature and poured onto ice cooled water. The formed precipitate was filtered off, dried and crystallized from aqueous ethanol to give 1.94 g of **5a** (65% yield); mp 161–163 °C; IR (cm⁻¹) 3420 (OH), 3104, 2955 (CH aromatic), 2924, 2851 (CH aliphatic), 1594 (C=N), 1500 (C=C aromatic); ¹H NMR (DMSOd₆) δ 2.27 (s, 6H, H₃C-N-CH₃), 3.58 (s, 2H, CH₂N), 7.34-8.12 (m, 12H, phenol H-3, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7, N=CH), 10.27 (s, 1H, OH, D₂O exchangeable); EIMS 387 (M⁺). Anal. Calcd for C₂₃H₂₁N₃OS: C, 71.29; H, 5.46; N, 10.84. Found: C, 70.98; H, 5.29; N, 10.58.

2.1.1.4. 4-[(4-benzothiazol-2-yl-phenylimino)methyl]-2-(piperidin-1-ylmethyl)phenol (**5b**). The title compound **5b** was synthesized, using a similar procedure to that described for the preparation of **5a**, by using piperidine in place of dimethylamine, in 62% yield as a pale brown powder; mp 110–112 °C; IR (cm⁻¹) 3420 (OH), 3096, 3027 (CH aromatic), 2932, 2801 (CH aliphatic), 1596 (C=N), 1516 (C=C aromatic); ¹H NMR (DMSOd₆) δ 1.00–1.12 (m, 6H, piperidine H-3, H-4, H-5), 2.22 (t, 4H, J = 5.1 Hz, piperidine H-2, H-6), 3.96 (s, 2H, CH₂N), 7.34–8.12 (m, 12H, phenol H-3, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7, N=CH), 10.27 (s, 1H, OH, D₂O exchangeable); EIMS 427 (M⁺). Anal. Calcd for C₂₆H₂₅N₃OS: C, 73.04; H, 5.89; N, 9.83. Found: C, 73.23; H, 5.73; N, 10.13.

2.1.1.5. N-(4-Benzothiazol-2-ylphenyl)-2-(4-

hydroxyphenylamino)acetamide (7). A mixture of N-(4benzothiazol-2-ylphenyl)-2-chloroacetamide (6) (1.5 g, 0.005 mol), 4-aminophenol (0.5 g, 0.005 mol) and few crystals Download English Version:

https://daneshyari.com/en/article/816576

Download Persian Version:

https://daneshyari.com/article/816576

Daneshyari.com